Company Encyclopedia
View More
name
JILIN CHANGLONG
08049.HK
Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products in the People’s Republic of China. The company provides Edaravone injection, compound brain comfort capsules, haikun kidney capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine zinc gluconate tablets, and Qianlie Guihuang Tablets. It markets its products under the Changlong and Qing Tong brands. The company also engages in the manufacture and distribution of beverages and prepackaged food.
1.412 T
08049.HKMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking14/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.03%B
    • Profit Margin19.74%A
    • Gross Margin82.40%A
  • Growth ScoreB
    • Revenue YoY10.65%B
    • Net Profit YoY6.76%C
    • Total Assets YoY14.07%B
    • Net Assets YoY11.37%B
  • Cash ScoreB
    • Cash Flow Margin506.59%C
    • OCF YoY10.65%B
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreB
    • Gearing Ratio34.58%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | JILIN CHANGLONG's main force tests again, is a medium-term swing opportunity emerging?

    JILIN CHANGLONG experienced moderate volume increase yesterday, with the pharmaceutical sector's stable style favored by funds in a volatile market. Funds gradually flowed back within three days, and the stock price returned above the 30-day moving average, indicating a noticeable warming of the short-term bullish atmosphere. Discussions in the community about the defensive attributes of pharmaceuticals have increased, with risk-averse funds continuing to position themselves. Favorable industry policies are frequently emerging, with dynamics such as medical insurance negotiations and innovative drug access supporting industry sentiment. The company's news front is stable, with light pressure for positioning at low levels. The market shows that defensive attributes have been activated, and short-term elasticity has strengthened due to increased funds. Technical wave signals are gradually being established, but continuity will depend on the sector's heat and volume expansion. If there is a surge during the session that is met with profit-taking by the main force or weakened trading volume, it may easily fall into consolidation and fluctuation. There is still a risk of pullback when chasing short-term gains, and wave opportunities need to closely monitor the sustainability of funds. The overall strategy should focus on steady progress, with stop-loss measures in place and a priority on gradual low absorption

    Technical Forecast·
    HK
    08049
    -0.45%
    Technical Forecast·
    HK
    08049
    -0.45%

    JILIN CHANGLONG subscribed to RMB 50 million of China Industrial and Commercial Bank wealth management products

    According to the Zhitong Finance APP, JILIN CHANGLONG announced that on August 25, 2025, the company subscribed to wealth management products from the Industrial and Commercial Bank of China for an amount of RMB 50 million

    Zhitong·
    SH
    601398
    -0.64%
    HK
    01398
    -0.49%
    HK
    08049
    -0.45%
    Zhitong·
    SH
    601398
    -0.64%
    HK
    01398
    -0.49%
    HK
    08049
    -0.45%

    JILIN CHANGLONG subscribed to ICBC wealth management products worth 50 million yuan

    According to the Zhitong Finance APP, JILIN CHANGLONG announced that on August 21, 2025, the company subscribed to wealth management products from ICBC for an amount of RMB 50 million

    Zhitong·
    SH
    601398
    -0.64%
    HK
    01398
    -0.49%
    HK
    08049
    -0.45%
    Zhitong·
    SH
    601398
    -0.64%
    HK
    01398
    -0.49%
    HK
    08049
    -0.45%

    JILIN CHANGLONG released its interim results, with a profit attributable to shareholders of 103 million yuan, a year-on-year decrease of 1.2%

    JILIN CHANGLONG released its interim results for the period ending June 30, 2025, with a revenue of 439 million yuan, an increase of 11.6% year-on-year. The profit attributable to shareholders was 103 million yuan, a decrease of 1.2% year-on-year. The basic earnings per share were 18.38 cents, with a marginal gross profit margin of approximately 82.4%, an increase compared to the same period last year, which the board believes is due to a reduction in production and material costs

    Zhitong·
    HK
    08049
    -0.45%
    Zhitong·
    HK
    08049
    -0.45%

    Zhitong Hong Kong Stock Investment Journal | July 18

    The Hong Kong stock investment log for July 18, 2025, includes new stock activities, earnings announcements, shareholder meetings, and dividend distribution information. The new stock WeiLiZhiBo-B is currently open for subscription, and several companies such as Emperor International Holdings and EVER REACH GP will announce their earnings. Shareholder meetings will be held by companies including Chow Tai Fook, and companies distributing dividends include JILIN CHANGLONG and CHINA PENGFEI. In addition, Luyiji Technology and Zhongzheng International will conduct capital increases

    Zhitong·
    HK
    03616
    -4.69%
    HK
    08049
    -0.45%
    HK
    03348
    -2.29%
    Zhitong·
    HK
    03616
    -4.69%
    HK
    08049
    -0.45%
    HK
    03348
    -2.29%
    © 2025 Longbridge｜Disclaimer